State Street Corp Has $54,000 Stake in Matinas Biopharma Holdings, Inc. (NYSE:MTNB)

State Street Corp reduced its holdings in Matinas Biopharma Holdings, Inc. (NYSE:MTNB) by 98.0% during the 3rd quarter, Holdings Channel reports. The fund owned 15,322 shares of the company’s stock after selling 750,749 shares during the quarter. State Street Corp’s holdings in Matinas Biopharma were worth $54,000 at the end of the most recent reporting period.

Separately, Highbridge Capital Management LLC acquired a new position in Matinas Biopharma in the second quarter worth $1,685,000. 11.77% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Maxim Group restated a “hold” rating on shares of Matinas Biopharma in a research note on Thursday, October 31st. Alliance Global Partners cut shares of Matinas Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 1st.

Matinas Biopharma Price Performance

MTNB stock opened at $0.64 on Friday. Matinas Biopharma Holdings, Inc. has a fifty-two week low of $0.48 and a fifty-two week high of $21.50. The company has a market capitalization of $3.23 million, a P/E ratio of -0.13 and a beta of 1.61.

Matinas Biopharma Company Profile

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.